Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Buy
59
NUS Quote, Financials, Valuation and Earnings
Last price:
$7.83
Seasonality move
:
6.86%
Day range:
$7.98 - $8.33
52-week range:
$5.95 - $14.04
Dividend yield:
2.92%
P/E ratio:
--
P/S ratio:
0.24x
P/B ratio:
0.63x
Volume:
654.7K
Avg. volume:
758K
1-year change:
-37.32%
Market cap:
$409.2M
Revenue:
$1.7B
EPS (TTM):
-$2.95
Analysts' Opinion
-
Consensus RatingNu Skin Enterprises has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $7.50, Nu Skin Enterprises has an estimated downside of -8.87% from its current price of $8.23.
-
Price Target UpsideAccording to analysts, the highest upside price target is $7.50 representing -100% upside increase from its current price of $8.23.
Fair Value
-
According to the consensus of 1 analyst, Nu Skin Enterprises has -8.87% downside to fair value with a price target of $7.50 per share.
NUS vs. S&P 500
-
Over the past 5 trading days, Nu Skin Enterprises has overperformed the S&P 500 by 10.65% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Nu Skin Enterprises does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nu Skin Enterprises revenues have been falling on a year-over-year basis for 14 quarters in a row. In the most recent quarter Nu Skin Enterprises reported revenues of $445.6M.
Earnings Growth
-
Nu Skin Enterprises earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Nu Skin Enterprises reported earnings per share of -$0.73.
Enterprise value:
604.8M
EV / Invested capital:
0.58x
Price / LTM sales:
0.24x
EV / EBIT:
14.90x
EV / Revenue:
0.35x
PEG ratio (5yr expected):
--
EV / Free cash flow:
8.62x
Price / Operating cash flow:
5.83x
Enterprise value / EBITDA:
65.52x
Gross Profit (TTM):
$1.2B
Return On Assets:
-8.95%
Net Income Margin (TTM):
-8.46%
Return On Equity:
-19.94%
Return On Invested Capital:
-12.32%
Operating Margin:
-1.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $2B | $1.7B | $488.6M | $445.6M | |
| Gross Profit | $1.6B | $1.4B | $1.2B | $352.4M | $279.1M | |
| Operating Income | $159.3M | $68.1M | $50.8M | $26.1M | -$7.2M | |
| EBITDA | $175M | $123.1M | -$78.8M | $35.3M | -$35.5M | |
| Diluted EPS | $2.07 | $0.18 | -$2.95 | $0.15 | -$0.73 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $903.2M | $873M | $759.9M | $701.9M | $538.6M | |
| Total Assets | $2B | $1.9B | $1.8B | $1.8B | $1.5B | |
| Current Liabilities | $542.9M | $529.7M | $359.2M | $328.9M | $296.6M | |
| Total Liabilities | $1.1B | $993.7M | $923.7M | $986.7M | $817.5M | |
| Total Equity | $894.3M | $912.8M | $897.3M | $822M | $651.5M | |
| Total Debt | $335.4M | $376.3M | $402.5M | $503M | $393.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $108.1M | $118.6M | $111.7M | $54.2M | $25.8M | |
| Cash From Investing | -$67.1M | -$134.5M | -$38M | -$15.4M | -$13.6M | |
| Cash From Financing | -$99.5M | $10.7M | -$133.2M | -$20.3M | -$43.6M | |
| Free Cash Flow | $49M | $60.1M | $70.2M | $33.8M | $13.2M | |
NUS
Sector
Market Cap
$409.2M
$294.3M
Price % of 52-Week High
58.62%
72.72%
Dividend Yield
2.92%
0%
Shareholder Yield
--
3.14%
1-Year Price Total Return
-37.32%
-11.28%
Beta (5-Year)
1.058
0.465
Dividend yield:
2.92%
Annualized payout:
$0.24
Payout ratio:
-8.14%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$7.95
200-day SMA
Sell
Level
$8.57
Bollinger Bands (100)
Buy
Level
6.43 - 7.61
Chaikin Money Flow
Buy
Level
19.1M
20-day SMA
Buy
Level
$7.48
Relative Strength Index (RSI14)
Buy
Level
63.42
ADX Line
Buy
Level
39.1
Williams %R
Sell
Level
-10.4167
50-day SMA
Buy
Level
$7.08
MACD (12, 26)
Buy
Level
0.32
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Sell
Level
-27.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9265)
Sell
CA Score
(Annual)
Level (-0.6905)
Buy
Beneish M-Score
(Annual)
Level (-3.4391)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.552)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
Stock Forecast FAQ
In the current month, NUS has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NUS average analyst price target in the past 3 months is $7.50.
-
Where Will Nu Skin Enterprises Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nu Skin Enterprises share price will drop to $7.50 per share over the next 12 months.
-
What Do Analysts Say About Nu Skin Enterprises?
Analysts are divided on their view about Nu Skin Enterprises share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nu Skin Enterprises is a Sell and believe this share price will rise from its current level to $7.50.
-
What Is Nu Skin Enterprises's Price Target?
The price target for Nu Skin Enterprises over the next 1-year time period is forecast to be $7.50 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nu Skin Enterprises is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of NUS?
You can purchase shares of Nu Skin Enterprises via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nu Skin Enterprises shares.
-
What Is The Nu Skin Enterprises Share Price Today?
Nu Skin Enterprises was last trading at $7.83 per share. This represents the most recent stock quote for Nu Skin Enterprises. Yesterday, Nu Skin Enterprises closed at $8.23 per share.
-
How To Buy Nu Skin Enterprises Stock Online?
In order to purchase Nu Skin Enterprises stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Is Walmart the Largest Retailer in the World?
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Stock Ideas
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
45
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
GH alert for Mar 12
Guardant Health [GH] is up 1.1% over the past day.
Sell
44
TER alert for Mar 12
Teradyne [TER] is down 0.36% over the past day.
Buy
57
LMB alert for Mar 12
Limbach Holdings [LMB] is down 4.39% over the past day.
